A Prospective, Multi-center, Observational Study for Signal-C Test Evaluation

RecruitingOBSERVATIONAL
Enrollment

15,000

Participants

Timeline

Start Date

January 18, 2024

Primary Completion Date

December 30, 2025

Study Completion Date

March 1, 2026

Conditions
Colorectal CancerAdvanced Adenocarcinoma
Interventions
DEVICE

Signal-C™

Signal-C™ is a qualitative next generation sequencing-based in vitro diagnostic assay that uses targeted hybridization-based capture next-generation sequencing together with bioinformatics and machine learning algorithm for detection and combination of methylation and fragmentation associated DNA marker regions. Signal-C™ utilizes circulating cell-free DNA (cfDNA) isolated from plasma of peripheral whole blood collected via venipuncture in Streck Cell-Free DNA Blood Collection Tubes (BCTs).

Trial Locations (1)

24502

RECRUITING

Blue Ridge Medical Research, Lynchburg

All Listed Sponsors
collaborator

Premier Research Group plc

UNKNOWN

collaborator

Yanuvia, LLC

UNKNOWN

collaborator

Science 37

INDUSTRY

lead

Universal Diagnostics

INDUSTRY